Literature DB >> 15041736

Orthotopic implantation of human hepatocellular carcinoma in mice: analysis of tumor progression and establishment of the BCLC-9 cell line.

Carolina Armengol1, Gemma Tarafa, Loreto Boix, Manel Solé, Rosa Queralt, Dolors Costa, Oriol Bachs, Jordi Bruix, Gabriel Capellá.   

Abstract

PURPOSE: To allow the longitudinal investigation of molecular events associated with the progression of human hepatocellular carcinoma (HCC), we sought to develop a murine model by orthotopic implantation of tumor fragments obtained from patients diagnosed at early stage. EXPERIMENTAL
DESIGN: Tumor pieces (2 x 2 mm) were implanted on the liver surface of nu/nu mice. After xenograft growing, subsequent passages were performed to achieve long-term implant viability. Isolation of tumoral hepatocytes was done to establish new cell lines. HCC characteristics, proliferation rate, apoptotic index (terminal deoxynucleotidyl transferase-mediated nick end labeling), and expression of cell-cycle regulators (cyclins E and A, p21(Cip1), p27(Kip1), p16(INK4a), pRb, and p53) were assessed by Western Blot and immunohistochemistry, to correlate them with tumor progression.
RESULTS: Five (50%) of the 10 primary HCCs resulted in small slow-growing liver implants. Three of them are viable after 48 months, whereas the remaining two survived for 15 and 13 months. Xenografts throughout passages exhibited a more aggressive phenotype with a poorer degree of differentiation, intense proliferation, moderate apoptosis, cell-cycle deregulation, p53 alterations, microvascular invasion, and dissemination. In one single passage, we observed critical growth delay, which was associated with significant p27(kip1) overexpression. We established the anchor-free growing BCLC-9 cell line from one xenograft. This has gains of chromosomes 7, 5p, 6q, and 9q, is hepatitis B virus-DNA positive, does not secrete alpha-fetoprotein, and has TP53 missense mutations in codons 192 and 242.
CONCLUSIONS: The orthotopic implantation of early HCC fragments in nude mice provides a useful model to investigate the mechanisms of human HCC evolution and to establish new cell lines.

Entities:  

Mesh:

Year:  2004        PMID: 15041736     DOI: 10.1158/1078-0432.ccr-03-1028

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

1.  IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.

Authors:  Victoria Tovar; Clara Alsinet; Augusto Villanueva; Yujin Hoshida; Derek Y Chiang; Manel Solé; Swan Thung; Susana Moyano; Sara Toffanin; Beatriz Mínguez; Laia Cabellos; Judit Peix; Myron Schwartz; Vincenzo Mazzaferro; Jordi Bruix; Josep M Llovet
Journal:  J Hepatol       Date:  2010-02-13       Impact factor: 25.083

2.  Rapid induction of orthotopic hepatocellular carcinoma in immune-competent rats by non-invasive ultrasound-guided cells implantation.

Authors:  Hoi-Hung Chan; Tian-Huei Chu; Hsin-Fan Chien; Cheuk-Kwan Sun; E-Ming Wang; Huay-Ben Pan; Hsiao-Mei Kuo; Tsung-Hui Hu; Kwok-Hung Lai; Jiin-Tsuey Cheng; Ming-Hong Tai
Journal:  BMC Gastroenterol       Date:  2010-07-22       Impact factor: 3.067

Review 3.  Establishment of animal models with orthotopic hepatocellular carcinoma.

Authors:  Tai Kyoung Lee; Kyung Sook Na; Jeonghun Kim; Hwan-Jeong Jeong
Journal:  Nucl Med Mol Imaging       Date:  2014-07-29

Review 4.  Experimental models of hepatocellular carcinoma: developments and evolution.

Authors:  Long Wu; Zhao-You Tang; Yan Li
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-28       Impact factor: 4.553

5.  Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine.

Authors:  Lidia Mingorance; Martina Friesland; Mairene Coto-Llerena; Sofía Pérez-del-Pulgar; Loreto Boix; Juan Manuel López-Oliva; Jordi Bruix; Xavier Forns; Pablo Gastaminza
Journal:  Antimicrob Agents Chemother       Date:  2014-04-07       Impact factor: 5.191

Review 6.  Hepatocellular carcinoma: Review of disease and tumor biomarkers.

Authors:  Jin Un Kim; Mohamed I F Shariff; Mary M E Crossey; Maria Gomez-Romero; Elaine Holmes; I Jane Cox; Haddy K S Fye; Ramou Njie; Simon D Taylor-Robinson
Journal:  World J Hepatol       Date:  2016-04-08

7.  Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development.

Authors:  Qingyang Gu; Bin Zhang; Hongye Sun; Qiang Xu; Yexiong Tan; Guan Wang; Qin Luo; Weiguo Xu; Shuqun Yang; Jian Li; Jing Fu; Lei Chen; Shengxian Yuan; Guibai Liang; Qunsheng Ji; Shu-Hui Chen; Chi-Chung Chan; Weiping Zhou; Xiaowei Xu; Hongyang Wang; Douglas D Fang
Journal:  Oncotarget       Date:  2015-08-21

8.  Molecularly characterised xenograft tumour mouse models: valuable tools for evaluation of new therapeutic strategies for secondary liver cancers.

Authors:  Daniela Mischek; Ralf Steinborn; Helga Petznek; Christoph Bichler; Kurt Zatloukal; Michael Stürzl; Walter H Günzburg; Christine Hohenadl
Journal:  J Biomed Biotechnol       Date:  2009-03-15

9.  Multimodal imaging of a humanized orthotopic model of hepatocellular carcinoma in immunodeficient mice.

Authors:  Tao Wu; Emilie Heuillard; Véronique Lindner; Ghina Bou About; Mihaela Ignat; Jean-Philippe Dillenseger; Nicolas Anton; Eugénie Dalimier; Francine Gossé; Gael Fouré; Franck Blindauer; Céline Giraudeau; Hussein El-Saghire; Mourad Bouhadjar; Cynthia Calligaro; Tania Sorg; Philippe Choquet; Thierry Vandamme; Christophe Ferrand; Jacques Marescaux; Thomas F Baumert; Michele Diana; Patrick Pessaux; Eric Robinet
Journal:  Sci Rep       Date:  2016-10-14       Impact factor: 4.996

10.  Restoring miR122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through Smad-independent TGF-β pathway.

Authors:  Loreto Boix; Juan Manuel López-Oliva; Ana Carolina Rhodes; Jordi Bruix
Journal:  Oncotarget       Date:  2016-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.